According to the NORD, Von Hippel-Lindau (VHL) disease affects 1 in 36,000 people. As per DelveInsight’s analysis, the total US Von Hippel-Lindau disease prevalence was 9.2 thousand in 2020. Von Hippel-Lindau Market is expected to expand at a CAGR of 8.3% by 2030 in the 7MM owing to the increasing prevalence and emerging therapies.
Due to the rarity of the condition, the therapies would be eligible for market exclusivity, premium prices, and relaxed clinical trial guidelines, which is attracting pharmaceutical companies such as Merck, Novartis, and others to explore the Von Hippel-Lindau Therapeutics Market. The launch of the emerging therapies including Belzutifan (MK-6482), DFF332, and others is expected to improve the treatment scenario in the coming years.
For more details, visit:
Von Hippel-Lindau Therapeutics Market